ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0798

The Impact of Comorbidities on the Simple Disease Activity Index (SDAI) and Its Components over the First Year of Follow-up – an Analysis from the Canadian Early Arthritis Cohort (CATCH)

Lillian-Ruiheng Chen1, Orit Schieir2, Marie-France Valois3, Janet Pope4, Susan Bartlett3, Gilles Boire5, Glen Hazlewood6, Carol Hitchon7, Edward C. Keystone8, Diane Tin9, Carter Thorne10, Narcisse Singbo1, Vivian Bykerk11 and Louis Bessette12, 1Centre de recherche du CHU de Québec-Université Laval, Québec City, QC, Canada, 2Canadian Early Arthritis Cohort Study, Montréal, QC, Canada, 3McGill University, Montréal, QC, Canada, 4University of Western Ontario, London, ON, Canada, 5Universite de Sherbrooke, Sherbrooke, QC, Canada, 6University of Calgary, Calgary, AB, Canada, 7University of Manitoba, Winnipeg, MB, Canada, 8Mount Sinai Hospital, Toronto, ON, Canada, 9The Arthritis Program Research Group, Newmarket, ON, Canada, 10Southlake Regional Health Centre, Newmarket, ON, Canada, 11Hospital for Special Surgery, New York, NY, 12Centre de l'Ostoporose et de Rhumatologie de Qubec, Québec City, QC, Canada

Meeting: ACR Convergence 2021

Keywords: Comorbidity, Disease Activity, Patient reported outcomes, quality of life, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 7, 2021

Title: RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)

Session Type: Poster Session B

Session Time: 8:30AM-10:30AM

Background/Purpose: Comorbid conditions have been shown to negatively influence the achievement of treatment targets in rheumatoid arthritis (RA) patients. The comorbid conditions may bias the subjective measures of the widely used indices for evaluation of disease activity. The objective is to look at the relationships between comorbidities and components of common clinical disease activity scores, such as tender (TJC) and swollen (SJC) joint count, patient global assessment (PtGA), physician global assessment (MDGA), C-reactive protein (CRP) and pain in early RA.

Methods: Using a validated tool for the assessment of comorbidity burden specifically developed for rheumatology, the Rheumatic Disease Comorbidity Index (RDCI), the influence of comorbidities on each component’s trajectory in time has been assessed in early rheumatoid arthritis (ERA) patients over the first year of treatment with conventional synthetic DMARDS using data from the Canadian Early Arthritis Cohort (CATCH). The adjusted effects of RDCI scores (0, 1, 2, and ≥ 3) on the trajectory of the SDAI, on each component of the SDAI, and on pain (visual analog scale) was evaluated over the first year of follow-up with generalized estimating equations (GEE). Data were adjusted for possible confounders including baseline sociodemographic factors, disease activity and treatments.

Results: This sample size included 2248 ERA patients with a mean symptom duration (SD) of 5.71 (2.96) months; mean age (SD) was 55 (15) years old and 72% were female. At baseline, 1664 (74%) were treated with methotrexate with a mean weekly dose (SD) of 20.0 mg (4.2) and 1340 (60%) also received other conventional synthetic DMARDs. The mean (SD) SDAI at enrolment was 29 (15) and 90% were classified as having moderate-high SDAI. RDCI scores of 0, 1, 2 or ³3 were obtained in 888 (40%), 547 (24%), 451 (20%), and 362 (16%) participants, respectively. Although disease activity did not differ by comorbidity status at baseline, patients with RDCI of 0 had better improvement (rate of change) in SDAI (Figure 1), PtGA, MDGA and pain (Figure 2a,b,c) over time relative to patients with multiple RDCI conditions (p< 0.05). A significant higher rate of change in SJC was observed in patients with RDCI of 1 and 2 compared with participants having higher RDCI score (p= 0.01) (Figure 2d). The RDCI scores were not significantly associated with the change of TJC and CRP (Figure 2e and f) over one year.

Conclusion: In this ERA cohort, having multiple comorbidities was associated with worse improvement and disease activity assessed by SDAI over the first year of treatment. SJC, PtGA, and MDGA were the components of SDAI that were most influenced by the presence of comorbidities. The results demonstrate a negative effect of having comorbidities at disease onset of RA on the evolution of both patients and physicians reported outcomes.

Adjusted effects of RDCI on trajectory (predictive margins) of SDAI over the first year follow-up in patients with ERA

Adjusted effects of RDCI on trajectory (predictive margins) of PtGA, MDGA, pain, and SJC over the first-year follow-up in patients with ERA


Disclosures: L. Chen, None; O. Schieir, None; M. Valois, None; J. Pope, AbbVie, 2, Amgen, 2, Bayer, 2, Bristol-Myers Squibb, 2, 5, Eli Lilly, 2, Merck, 2, Novartis, 2, Pfizer Inc, 2, Roche, 2, 5, Sanofi, 2, Seattle Genetics, 5, UCB, 2, 5, Actelion, 2, Sandoz, 2; S. Bartlett, Merck Canada, 2, 6, Pfizer Canada, 2, 6, Janssen Canada, 2, 6, PROMIS Health Organization, 4, American Thoracic Society, 4, Arthritis Health Professionals Association, 4, UCB, 1, RAND Corporation, 1; G. Boire, Abbvie, 1, 6, 7, BMS, 6, 7, Janssen, 1, 5, 6, Eli Lilly, 1, 7, Amgen, 7, Novartis, 6, 7, Pfizer, 7, Sandoz, 6, 7, Viatris, 1, 6, Samsung Bioepis, 1; G. Hazlewood, None; C. Hitchon, None; E. Keystone, Abbott, 2, 5, 6, Amgen, 2, 5, 6, Astra Zeneca, 2, 5, 6, Biotest, 2, 5, 6, Bristol-Meyers-Squibb, 2, 5, 6, Hoffman-La Roche, 2, 5, 6, Janssen, 2, 5, 6, Eli Lilly and Company, 2, 5, 6, Genentech, 2, 5, 6, Merck, 2, 5, 6, Novartis, 2, 5, 6, Pfizer, 2, 5, 6, Sanofi-Aventis, 2, 5, 6, UCB, 5, 6; D. Tin, None; C. Thorne, AbbVie, 1, Amgen Inc, 1, Celgene, 1, Eli Lilly, 1, Medexus/Medac, 1, 2, 6, Merck, 1, 2, Novartis, 1, 5, Pfizer, 1, 5, Sandoz, 1, Sanofi, 1, Centocor, 2; N. Singbo, None; V. Bykerk, Amgen Inc., 2, 6, Bristol Myers Squibb, 2, 6, Gilead, 2, 6, Pfizer, 2, 6, Regeneron, 2, 6, Sanofi-Genzyme, 2, 6, UCB, 2, 6; L. Bessette, Amgen, 2, 5, 6, Bristol-Myers Squibb, 2, 5, 6, Janssen, 2, 5, 6, Roche, 2, 5, 6, UCB, 2, 5, 6, AbbVie, 2, 5, 6, Pfizer, 2, 5, 6, Merck & Co, 2, 5, Celgene, 2, 5, 6, Sanofi, 2, 5, 6, Eli Lilly, 2, 5, 6, Novartis, 2, 5, 6, Gilead, 2, 5, 6, Sandoz, 2, 5, 6, Teva, 2, 6.

To cite this abstract in AMA style:

Chen L, Schieir O, Valois M, Pope J, Bartlett S, Boire G, Hazlewood G, Hitchon C, Keystone E, Tin D, Thorne C, Singbo N, Bykerk V, Bessette L. The Impact of Comorbidities on the Simple Disease Activity Index (SDAI) and Its Components over the First Year of Follow-up – an Analysis from the Canadian Early Arthritis Cohort (CATCH) [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/the-impact-of-comorbidities-on-the-simple-disease-activity-index-sdai-and-its-components-over-the-first-year-of-follow-up-an-analysis-from-the-canadian-early-arthritis-cohort-catch/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-impact-of-comorbidities-on-the-simple-disease-activity-index-sdai-and-its-components-over-the-first-year-of-follow-up-an-analysis-from-the-canadian-early-arthritis-cohort-catch/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology